Lin Bioscience (6696.TWO) Stock Price

Lin Bioscience Price

CLOSED
161.50
​
Market closed

Lin Bioscience stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lin Bioscience business model & stock analysis

Lin BioScience, Inc. engages in the development of drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-10-08. The firm is in the research and development and clinical trials stage. The company has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.

Frequently asked questions about Lin Bioscience

Converted at the current exchange rate, the Lin Bioscience share trades at 4.43 EUR (161.50 TWD).

The revenue cannot currently be calculated for Lin Bioscience.

The profit cannot currently be calculated for Lin Bioscience.

The P/E ratio cannot be calculated for Lin Bioscience at the moment.

The P/S cannot be calculated for Lin Bioscience currently.

The Eulerpool Quality Score for Lin Bioscience is 2/10.

The ISIN of Lin Bioscience is TW0006696008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Lin Bioscience is 6696.TWO. The ticker symbol is used to trade Lin Bioscience shares on the stock exchange.

Fair ValueTerminal
167.96 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Oct 8, 2018
ISIN
TW0006696008
Cusip
Y528A2107
Market capitalization
13.36 B TWDLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.24
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-12.70 %
Last updated Oct 20, 2026, 8:33 AM

Lin Bioscience Peer Group

Lin Bioscience FIGI

6696:TT (Taipei Stock Exchange) · BBG00M3JS3K7